智慧鬆德(300173.SZ):持股5%以上股東雷萬春擬減持不超2.4%股份
格隆匯 6 月 22日丨智慧鬆德(300173.SZ)公佈,公司持股5%以上股東雷萬春持有公司股份4941.31萬股,佔公司總股本比例為7.38%,雷萬春計劃自公告日起15個交易日後的6個月內以集中競價或大宗交易等深圳證券交易所認可的其他合法方式減持公司股份合計不超過1605.6萬股,減持比例合計不超過公司目前總股本比例的2.40%。此次擬減持價格:4元—15元,視減持實施時的市場價格確定。
其中採取集中競價交易方式的,在任意連續90個自然日內減持總數不超過公司目前總股本比例的1%;採取大宗交易方式的,在任意連續90個自然日內減持總數不超過公司目前總股本比例的2%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.